| A systematic review of randomized evidence for fibrinogen-depleting agents in acute ischemic stroke. | |
| | |
MedLine Citation:
|
PMID: 17895058 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess the efficacy and safety of fibrinogen-depleting agents (snake venom extracts) in the treatment of acute ischemic stroke. METHODS: A systematic review of all the relevant randomized controlled trials (RCTs) was performed. RCTs were identified from the Cochrane Stroke Group's Specialized Trial Register, additional electronic and hand searching, and personal contact with pharmaceutical companies. We included all completed and unconfounded truly or quasi-randomized trials in patients with ischemic stroke comparing fibrinogen depleting agents with control started within 14 days of the stroke onset. The Peto method was used for analysis. RESULTS: Eight completed and two ongoing RCTs have been identified so far. Only three trials using ancrod (182 patients) met the inclusion criteria. Ancrod was associated with a significant reduction in early deaths (5.6% v 16%; odds ratio [OR], 0.33; 95% confidence interval [CI], 0.13 to 0.85; 2P=.02) suggesting that treatment of 100 patients would avoid about 10 early deaths. The frequency of asymptomatic intracranial hemorrhage shown by computed tomography was similar between ancrod-treated and control groups (7.6% v 9.6%; OR, 0.78; 95% CI, 0.26 to 2.33; 2P=.65). No major intracranial or extracranial hemorrhages or recurrent ischemic strokes occurred in the ancrod-allocated patients. There were nonsignificant trends in favor of ancrod in death from any cause (OR, 0.57; 95% CI, 0.27 to 1.23; 2P=.15) and death or disability (OR, 0.52; 95% CI, 0.26 to 1.03; 2P=.06) at the end of trial follow-up. CONCLUSIONS: There were too few patients and outcome events to draw reliable conclusions from the present data. Although ancrod-like agents appeared promising, their routine use cannot be recommended at the moment. Two ongoing trials (including about 1,000 patients in total) will provide more data. Future trials should test simpler fixed-dose regimens to allow better generalizability. |
| | |
Authors:
|
M Liu; C Counsell; J Wardlaw; P Sandercock |
Related Documents
:
|
16855978 - Topical treatments for cutaneous warts. 15728168 - Evaluation of new treatments in radiation oncology: are they better than standard treat... 19382398 - Dexrazoxane: new indication. anthracycline extravasation: continue using dimethyl sulfo... 16626978 - An integrated analysis of five double-blind, randomized controlled trials evaluating th... 20051928 - Viral coinfections in children with invasive pneumococcal disease. 7177648 - Orthoptic treatment in teenage patients. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association Volume: 7 ISSN: 1052-3057 ISO Abbreviation: J Stroke Cerebrovasc Dis Publication Date: 1998 Jan-Feb |
Date Detail:
|
Created Date: 2007-09-26 Completed Date: 2009-12-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9111633 Medline TA: J Stroke Cerebrovasc Dis Country: United States |
Other Details:
|
Languages: eng Pagination: 63-9 Citation Subset: - |
Affiliation:
|
Department of Clinical Neurosciences, University of Edinburgh, Scotland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Accelerated bone remodeling in patients with poststroke hemiplegia.
Next Document: Health-related quality of life after transient ischemic attack and minor stroke: Is medical or surgi...